LONDON — Novo Nordisk, under new leadership and in need of a boost, said Wednesday it would trim 9,000 jobs — roughly 11% of its workforce — as it seeks to remake itself for a more competitive obesity drug market.

The cuts are designed to save the Danish firm $1.26 billion a year by the end of 2026, and are part of what Novo described as a broader transformation that will simplify the company’s organization, speed up its decision making, and push more resources toward building growth in its diabetes and obesity businesses.

Roughly 5,000 of the job losses will be in Denmark. Novo has more than 78,000 employees.

“It is always difficult to see talented and valued colleagues go, but we are convinced that this is the right thing to do for the long-term success of Novo Nordisk,” Mike Doustda

See Full Page